

Dear Madam, Sir,

Thank you for your interest in SkinVision. The following document summarizes our pricing for our NHS partners. We're available to meet with you and your team and discuss this in more detail.

### Pricing of SkinVision

NHS organisations may purchase bundles of SkinVision year plans (unlimited access for 12 months) at a discounted price. We offer the following tiered pricing:

| # of accounts | Price / account     | Total Price |
|---------------|---------------------|-------------|
| 1.000         | £ 20 (20% discount) | £ 20.000    |
| 5.000         | £ 15 (40% discount) | £ 75.000    |
| 10.000        | £ 12 (52% discount) | £120.000    |
| >50.000       | £ 10 (60% discount) | £500.000    |

We want to build a partnership where both of us enjoy benefits and as such, we'll never charge for any customers who are not active users of SkinVision, i.e. we only count accounts that became active on our platform as part of the bundle.

This price includes SkinVision IT development, program management, marketing & activation campaign materials and monthly dashboards on activity and results. There are no additional costs for onboarding or offboarding the program. Prices exclude VAT.


### Alternative pricing models

SkinVision can also support alternative pricing models, including a value based healthcare agreement where we receive a compensation for every high risk skin lesion that we identify. This investment is then directly related to cost savings further down the skin cancer care pathway.

We're happy to start a conversation with you on how we can best make our service affordable to your population.

### SkinVision realizes significant health benefits

The investment in SkinVision is justified, as our services generates significant health benefits further down the care pathway. We serves as a filter to the healthcare system, relieving pressure on the health system by reducing the number of unnecessary consultations and unnecessary urgent referrals. At the same time, we drive early recognition of skin cancer by enabling patients to find treatment in an early stage when the disease is much better and much cheaper to treat.



We look forward to working with you on this project and establishing a strong partnership between our companies going forward.

Yours sincerely,  
Loes van Egmond  
*NHS Innovation Accelerator Fellow and B2B Program Manager*